$EIDX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Eidos Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Eidos Therapeutics, Inc.. Get notifications about new insider transactions in Eidos Therapeutics, Inc. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jan 28 2021 | EIDX | Eidos Therapeutics ... | Fox Jonathan C | See Remarks | Option Exercise | D | 13.20 | 70,000 | 924,000 | 0 | |
Jan 28 2021 | EIDX | Eidos Therapeutics ... | Fox Jonathan C | See Remarks | Sell | U | 0.00 | 380,467 | 0 | 0 | 380.5 K to 0 (-100.00 %) |
Jan 28 2021 | EIDX | Eidos Therapeutics ... | Fox Jonathan C | See Remarks | Gift | G | 0.00 | 500 | 0 | 380,467 | 381 K to 380.5 K (-0.13 %) |
Jan 28 2021 | EIDX | Eidos Therapeutics ... | Rohlen Douglas | Director | Option Exercise | D | 0.00 | 4,526 | 0 | 0 | |
Jan 28 2021 | EIDX | Eidos Therapeutics ... | Rohlen Douglas | Director | Option Exercise | D | 41.42 | 21,447 | 888,335 | 0 | |
Jan 28 2021 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Option Exercise | D | 7.24 | 24,350 | 176,294 | 0 | |
Jan 28 2021 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Option Exercise | D | 13.20 | 53,157 | 701,672 | 0 | |
Jan 28 2021 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Option Exercise | D | 17.00 | 9,469 | 160,973 | 0 | |
Jan 28 2021 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Sell | U | 0.00 | 50,699 | 0 | 0 | 50.7 K to 0 (-100.00 %) |
Jan 28 2021 | EIDX | Eidos Therapeutics ... | Satvat Ali J. | Director | Option Exercise | D | 20.34 | 43,056 | 875,759 | 0 | |
Jan 28 2021 | EIDX | Eidos Therapeutics ... | Satvat Ali J. | Director | Option Exercise | D | 30.87 | 21,528 | 664,569 | 0 | |
Jan 28 2021 | EIDX | Eidos Therapeutics ... | Satvat Ali J. | Director | Option Exercise | D | 48.51 | 21,528 | 1,044,323 | 0 | |
Jan 28 2021 | EIDX | Eidos Therapeutics ... | Lis William | Director | Option Exercise | D | 13.67 | 43,056 | 588,576 | 0 | |
Jan 28 2021 | EIDX | Eidos Therapeutics ... | Lis William | Director | Option Exercise | D | 30.87 | 21,528 | 664,569 | 0 | |
Jan 28 2021 | EIDX | Eidos Therapeutics ... | Lis William | Director | Option Exercise | D | 48.51 | 21,528 | 1,044,323 | 0 | |
Jan 28 2021 | EIDX | Eidos Therapeutics ... | Hooper Suzanne Sawochka | Director | Option Exercise | D | 0.00 | 4,526 | 0 | 0 | |
Jan 28 2021 | EIDX | Eidos Therapeutics ... | Hooper Suzanne Sawochka | Director | Option Exercise | D | 41.42 | 21,447 | 888,335 | 0 | |
Jan 28 2021 | EIDX | Eidos Therapeutics ... | Sinha Uma | Chief Scientific Of ... | Option Exercise | D | 13.20 | 60,000 | 792,000 | 0 | |
Jan 28 2021 | EIDX | Eidos Therapeutics ... | Sinha Uma | Chief Scientific Of ... | Sell | U | 0.00 | 303,525 | 0 | 0 | 303.5 K to 0 (-100.00 %) |
Jan 28 2021 | EIDX | Eidos Therapeutics ... | Sinha Uma | Chief Scientific Of ... | Gift | G | 0.00 | 3,000 | 0 | 303,525 | 306.5 K to 303.5 K (-0.98 %) |
Jan 26 2021 | EIDX | Eidos Therapeutics ... | BridgeBio Pharma, Inc. | 10% Owner | Buy | P | 0.00 | 14,428,836 | 0 | 1,000 | -14,427,836 to 1,000 (-100.01 %) |
Jan 15 2021 | EIDX | Eidos Therapeutics ... | Sinha Uma | Chief Scientific Of ... | Sell | S | 126.39 | 300 | 37,917 | 306,525 | 306.8 K to 306.5 K (-0.10 %) |
Jan 15 2021 | EIDX | Eidos Therapeutics ... | Sinha Uma | Chief Scientific Of ... | Sell | S | 125.35 | 2,000 | 250,700 | 306,825 | 308.8 K to 306.8 K (-0.65 %) |
Jan 15 2021 | EIDX | Eidos Therapeutics ... | Sinha Uma | Chief Scientific Of ... | Sell | S | 124.72 | 4,934 | 615,362 | 308,825 | 313.8 K to 308.8 K (-1.57 %) |
Jan 15 2021 | EIDX | Eidos Therapeutics ... | Sinha Uma | Chief Scientific Of ... | Sell | S | 123.48 | 1,498 | 184,971 | 313,759 | 315.3 K to 313.8 K (-0.48 %) |
Jan 15 2021 | EIDX | Eidos Therapeutics ... | Sinha Uma | Chief Scientific Of ... | Sell | S | 122.27 | 572 | 69,937 | 315,257 | 315.8 K to 315.3 K (-0.18 %) |
Jan 15 2021 | EIDX | Eidos Therapeutics ... | Sinha Uma | Chief Scientific Of ... | Sell | S | 121.11 | 696 | 84,292 | 315,829 | 316.5 K to 315.8 K (-0.22 %) |
Jan 13 2021 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Option Exercise | M | 7.24 | 1,747 | 12,648 | 24,350 | |
Jan 13 2021 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Option Exercise | M | 7.24 | 1,500 | 10,860 | 26,097 | |
Jan 13 2021 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Sell | S | 125.45 | 1,747 | 219,152 | 0 | 1.7 K to 0 (-100.00 %) |
Jan 13 2021 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Buy | M | 7.24 | 1,747 | 12,648 | 1,747 | 0 to 1.7 K |
Jan 13 2021 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Sell | S | 125.61 | 1,500 | 188,408 | 0 | 1.5 K to 0 (-100.00 %) |
Jan 13 2021 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Buy | M | 7.24 | 1,500 | 10,860 | 1,500 | 0 to 1.5 K |
Dec 16 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Option Exercise | M | 13.20 | 21,843 | 288,328 | 53,157 | |
Dec 16 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Option Exercise | M | 17.00 | 4,451 | 75,667 | 9,469 | |
Dec 16 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Sell | S | 112.97 | 3,493 | 394,589 | 50,621 | 54.1 K to 50.6 K (-6.45 %) |
Dec 16 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Sell | S | 112.19 | 11,445 | 1,284,018 | 54,114 | 65.6 K to 54.1 K (-17.46 %) |
Dec 16 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Sell | S | 111.31 | 7,600 | 845,937 | 65,559 | 73.2 K to 65.6 K (-10.39 %) |
Dec 16 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Sell | S | 110.29 | 3,756 | 414,251 | 73,159 | 76.9 K to 73.2 K (-4.88 %) |
Dec 16 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Buy | M | 13.20 | 21,843 | 288,328 | 76,915 | 55.1 K to 76.9 K (+39.66 %) |
Dec 16 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Buy | M | 17.00 | 4,451 | 75,667 | 55,072 | 50.6 K to 55.1 K (+8.79 %) |
Dec 04 2020 | EIDX | Eidos Therapeutics ... | Sinha Uma | Chief Scientific Of ... | Sell | S | 92.97 | 200 | 18,593 | 316,525 | 316.7 K to 316.5 K (-0.06 %) |
Dec 04 2020 | EIDX | Eidos Therapeutics ... | Sinha Uma | Chief Scientific Of ... | Sell | S | 91.89 | 300 | 27,567 | 316,725 | 317 K to 316.7 K (-0.09 %) |
Dec 04 2020 | EIDX | Eidos Therapeutics ... | Sinha Uma | Chief Scientific Of ... | Sell | S | 90.63 | 702 | 63,625 | 317,025 | 317.7 K to 317 K (-0.22 %) |
Dec 04 2020 | EIDX | Eidos Therapeutics ... | Sinha Uma | Chief Scientific Of ... | Sell | S | 89.63 | 3,798 | 340,402 | 317,727 | 321.5 K to 317.7 K (-1.18 %) |
Nov 13 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Gift | G | 0.00 | 1,500 | 0 | 50,621 | 52.1 K to 50.6 K (-2.88 %) |
Nov 13 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Sell | S | 75.23 | 908 | 68,308 | 52,121 | 53 K to 52.1 K (-1.71 %) |
Nov 13 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Sell | S | 74.75 | 9,497 | 709,860 | 53,029 | 62.5 K to 53 K (-15.19 %) |
Nov 13 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Sell | S | 73.56 | 3,005 | 221,060 | 62,526 | 65.5 K to 62.5 K (-4.59 %) |
Nov 03 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Option Exercise | M | 17.00 | 2,500 | 42,500 | 13,920 | |
Nov 03 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Option Exercise | M | 13.20 | 5,000 | 66,000 | 75,000 | |
Nov 03 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Sell | S | 72.10 | 209 | 15,068 | 65,531 | 65.7 K to 65.5 K (-0.32 %) |
Nov 03 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Sell | S | 71.42 | 3,146 | 224,677 | 65,740 | 68.9 K to 65.7 K (-4.57 %) |
Nov 03 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Sell | S | 70.44 | 9,145 | 644,209 | 68,886 | 78 K to 68.9 K (-11.72 %) |
Nov 03 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Buy | M | 17.00 | 2,500 | 42,500 | 78,031 | 75.5 K to 78 K (+3.31 %) |
Nov 03 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Buy | M | 13.20 | 5,000 | 66,000 | 75,531 | 70.5 K to 75.5 K (+7.09 %) |
Oct 09 2020 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Option Exercise | M | 7.24 | 5,199 | 37,641 | 29,220 | |
Oct 09 2020 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Option Exercise | M | 7.24 | 5,000 | 36,200 | 34,419 | |
Oct 09 2020 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Sell | S | 74.85 | 5,199 | 389,151 | 0 | 5.2 K to 0 (-100.00 %) |
Oct 09 2020 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Buy | M | 7.24 | 5,199 | 37,641 | 5,199 | 0 to 5.2 K |
Oct 09 2020 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Sell | S | 75.08 | 5,444 | 408,748 | 0 | 5.4 K to 0 (-100.00 %) |
Oct 09 2020 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Buy | M | 7.24 | 5,000 | 36,200 | 5,444 | 444 to 5.4 K (+1,126.13 %) |
Oct 02 2020 | EIDX | Eidos Therapeutics ... | Sinha Uma | Chief Scientific Of ... | Sell | S | 52.35 | 4,831 | 252,923 | 326,525 | 331.4 K to 326.5 K (-1.46 %) |
Oct 02 2020 | EIDX | Eidos Therapeutics ... | Sinha Uma | Chief Scientific Of ... | Sell | S | 52.00 | 100 | 5,200 | 331,356 | 331.5 K to 331.4 K (-0.03 %) |
Oct 02 2020 | EIDX | Eidos Therapeutics ... | Sinha Uma | Chief Scientific Of ... | Sell | S | 52.08 | 69 | 3,594 | 331,456 | 331.5 K to 331.5 K (-0.02 %) |
Sep 18 2020 | EIDX | Eidos Therapeutics ... | Fox Jonathan C | See Remarks | Sell | S | 50.16 | 5,767 | 289,259 | 377,673 | 383.4 K to 377.7 K (-1.50 %) |
Sep 16 2020 | EIDX | Eidos Therapeutics ... | Fox Jonathan C | See Remarks | Sell | S | 50.16 | 3,122 | 156,610 | 383,440 | 386.6 K to 383.4 K (-0.81 %) |
Sep 16 2020 | EIDX | Eidos Therapeutics ... | Fox Jonathan C | See Remarks | Sell | S | 50.06 | 1,000 | 50,064 | 386,562 | 387.6 K to 386.6 K (-0.26 %) |
Sep 16 2020 | EIDX | Eidos Therapeutics ... | Fox Jonathan C | See Remarks | Sell | S | 50.00 | 111 | 5,550 | 387,562 | 387.7 K to 387.6 K (-0.03 %) |
Sep 11 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Option Exercise | M | 17.00 | 2,500 | 42,500 | 16,420 | |
Sep 11 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Sell | S | 47.00 | 2,500 | 117,500 | 70,531 | 73 K to 70.5 K (-3.42 %) |
Sep 11 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Buy | M | 17.00 | 2,500 | 42,500 | 73,031 | 70.5 K to 73 K (+3.54 %) |
Aug 10 2020 | EIDX | Eidos Therapeutics ... | Hooper Suzanne Sawochka | Director | Option Exercise | A | 41.42 | 21,447 | 888,335 | 21,447 | |
Aug 10 2020 | EIDX | Eidos Therapeutics ... | Hooper Suzanne Sawochka | Director | Option Exercise | A | 0.00 | 4,526 | 0 | 4,526 | |
Aug 10 2020 | EIDX | Eidos Therapeutics ... | Rohlen Douglas | Director | Option Exercise | A | 41.42 | 21,447 | 888,335 | 21,447 | |
Aug 10 2020 | EIDX | Eidos Therapeutics ... | Rohlen Douglas | Director | Option Exercise | A | 0.00 | 4,526 | 0 | 4,526 | |
Aug 05 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Option Exercise | M | 13.20 | 5,000 | 66,000 | 80,000 | |
Aug 05 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Sell | S | 40.89 | 500 | 20,446 | 70,531 | 71 K to 70.5 K (-0.70 %) |
Aug 05 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Sell | S | 40.25 | 6,700 | 269,672 | 71,031 | 77.7 K to 71 K (-8.62 %) |
Aug 05 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Sell | S | 39.05 | 2,800 | 109,332 | 77,731 | 80.5 K to 77.7 K (-3.48 %) |
Aug 05 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Buy | M | 13.20 | 5,000 | 66,000 | 80,531 | 75.5 K to 80.5 K (+6.62 %) |
Jul 09 2020 | EIDX | Eidos Therapeutics ... | Fox Jonathan C | See Remarks | Sell | S | 50.00 | 5,000 | 250,000 | 387,673 | 392.7 K to 387.7 K (-1.27 %) |
Jul 01 2020 | EIDX | Eidos Therapeutics ... | Fox Jonathan C | See Remarks | Buy | J | 0.00 | 1,088 | 0 | 392,673 | 391.6 K to 392.7 K (+0.28 %) |
Jun 05 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Grant | A | 41.57 | 376 | 15,632 | 75,531 | 75.2 K to 75.5 K (+0.50 %) |
Jun 05 2020 | EIDX | Eidos Therapeutics ... | Fox Jonathan C | See Remarks | Sell | S | 50.00 | 5,000 | 250,000 | 391,585 | 396.6 K to 391.6 K (-1.26 %) |
Jun 05 2020 | EIDX | Eidos Therapeutics ... | Fox Jonathan C | See Remarks | Gift | G | 0.00 | 1,020 | 0 | 396,585 | 397.6 K to 396.6 K (-0.26 %) |
Jun 05 2020 | EIDX | Eidos Therapeutics ... | Fox Jonathan C | See Remarks | Gift | G | 0.00 | 1,020 | 0 | 397,605 | 398.6 K to 397.6 K (-0.26 %) |
Jun 05 2020 | EIDX | Eidos Therapeutics ... | Fox Jonathan C | See Remarks | Grant | A | 41.57 | 444 | 18,459 | 3,294 | 2.9 K to 3.3 K (+15.58 %) |
Jun 05 2020 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Grant | A | 41.57 | 444 | 18,459 | 444 | 0 to 444 |
Jun 01 2020 | EIDX | Eidos Therapeutics ... | Fox Jonathan C | See Remarks | Sell | S | 50.00 | 5,000 | 250,000 | 398,625 | 403.6 K to 398.6 K (-1.24 %) |
May 29 2020 | EIDX | Eidos Therapeutics ... | AGUIAR ERIC | Director | Option Exercise | A | 48.51 | 21,528 | 1,044,323 | 21,528 | |
May 29 2020 | EIDX | Eidos Therapeutics ... | Shah Rajeev M. | Director | Option Exercise | A | 48.51 | 21,528 | 1,044,323 | 21,528 | |
May 29 2020 | EIDX | Eidos Therapeutics ... | Satvat Ali J. | Director | Option Exercise | A | 48.51 | 21,528 | 1,044,323 | 21,528 | |
May 28 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Option Exercise | M | 17.00 | 2,500 | 42,500 | 18,920 | |
May 28 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Sell | S | 47.00 | 2,500 | 117,500 | 75,155 | 77.7 K to 75.2 K (-3.22 %) |
May 28 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Buy | M | 17.00 | 2,500 | 42,500 | 77,655 | 75.2 K to 77.7 K (+3.33 %) |
May 05 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Option Exercise | M | 13.20 | 5,000 | 66,000 | 85,000 | |
May 05 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Sell | S | 43.26 | 20 | 865 | 75,155 | 75.2 K to 75.2 K (-0.03 %) |
May 05 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Sell | S | 42.56 | 1,180 | 50,220 | 75,175 | 76.4 K to 75.2 K (-1.55 %) |
May 05 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Sell | S | 41.23 | 1,050 | 43,287 | 76,355 | 77.4 K to 76.4 K (-1.36 %) |
May 05 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Sell | S | 40.52 | 7,750 | 314,061 | 77,405 | 85.2 K to 77.4 K (-9.10 %) |
May 05 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Buy | M | 13.20 | 5,000 | 66,000 | 85,155 | 80.2 K to 85.2 K (+6.24 %) |
Apr 27 2020 | EIDX | Eidos Therapeutics ... | Fox Jonathan C | See Remarks | Sell | S | 50.00 | 2,153 | 107,650 | 403,625 | 405.8 K to 403.6 K (-0.53 %) |
Apr 27 2020 | EIDX | Eidos Therapeutics ... | Fox Jonathan C | See Remarks | Sell | S | 50.00 | 2,847 | 142,350 | 405,778 | 408.6 K to 405.8 K (-0.70 %) |
Apr 22 2020 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Option Exercise | M | 7.24 | 2,000 | 14,480 | 39,419 | |
Apr 22 2020 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Sell | S | 49.79 | 2,000 | 99,580 | 0 | 2 K to 0 (-100.00 %) |
Apr 22 2020 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Buy | M | 7.24 | 2,000 | 14,480 | 2,000 | 0 to 2 K |
Mar 30 2020 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Option Exercise | M | 7.24 | 5,000 | 36,200 | 41,419 | |
Mar 30 2020 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Sell | S | 48.85 | 2,000 | 97,700 | 0 | 2 K to 0 (-100.00 %) |
Mar 30 2020 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Sell | S | 47.87 | 3,000 | 143,610 | 2,000 | 5 K to 2 K (-60.00 %) |
Mar 30 2020 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Buy | M | 7.24 | 5,000 | 36,200 | 5,000 | 0 to 5 K |
Mar 04 2020 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Option Exercise | M | 7.24 | 3,000 | 21,720 | 46,419 | |
Mar 04 2020 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Sell | S | 53.06 | 1,000 | 53,060 | 0 | 1,000 to 0 (-100.00 %) |
Mar 04 2020 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Sell | S | 51.96 | 2,000 | 103,920 | 1,000 | 3 K to 1,000 (-66.67 %) |
Mar 04 2020 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Buy | M | 7.24 | 3,000 | 21,720 | 3,000 | 0 to 3 K |
Mar 04 2020 | EIDX | Eidos Therapeutics ... | Fox Jonathan C | See Remarks | Sell | S | 51.57 | 10,000 | 515,706 | 408,625 | 418.6 K to 408.6 K (-2.39 %) |
Feb 19 2020 | EIDX | Eidos Therapeutics ... | Fox Jonathan C | See Remarks | Sell | S | 54.00 | 10,000 | 540,000 | 418,625 | 428.6 K to 418.6 K (-2.33 %) |
Feb 19 2020 | EIDX | Eidos Therapeutics ... | Fox Jonathan C | See Remarks | Gift | G | 0.00 | 1,632 | 0 | 428,625 | 430.3 K to 428.6 K (-0.38 %) |
Feb 05 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Option Exercise | M | 17.00 | 2,500 | 42,500 | 21,420 | |
Feb 05 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Option Exercise | M | 13.20 | 5,000 | 66,000 | 90,000 | |
Feb 05 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Sell | S | 53.89 | 7,211 | 388,636 | 80,155 | 87.4 K to 80.2 K (-8.25 %) |
Feb 05 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Sell | S | 53.32 | 5,289 | 282,004 | 87,366 | 92.7 K to 87.4 K (-5.71 %) |
Feb 05 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Buy | M | 17.00 | 2,500 | 42,500 | 92,655 | 90.2 K to 92.7 K (+2.77 %) |
Feb 05 2020 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Buy | M | 13.20 | 5,000 | 66,000 | 90,155 | 85.2 K to 90.2 K (+5.87 %) |
Jan 16 2020 | EIDX | Eidos Therapeutics ... | Fox Jonathan C | See Remarks | Sell | S | 55.00 | 3,580 | 196,900 | 430,257 | 433.8 K to 430.3 K (-0.83 %) |
Jan 16 2020 | EIDX | Eidos Therapeutics ... | Fox Jonathan C | See Remarks | Sell | S | 55.01 | 6,420 | 353,172 | 433,837 | 440.3 K to 433.8 K (-1.46 %) |
Jan 09 2020 | EIDX | Eidos Therapeutics ... | Fox Jonathan C | See Remarks | Gift | G | 0.00 | 100 | 0 | 440,257 | 440.4 K to 440.3 K (-0.02 %) |
Jan 09 2020 | EIDX | Eidos Therapeutics ... | Fox Jonathan C | See Remarks | Gift | G | 0.00 | 170 | 0 | 440,357 | 440.5 K to 440.4 K (-0.04 %) |
Dec 20 2019 | EIDX | Eidos Therapeutics ... | Sinha Uma | Chief Scientific Of ... | Sell | S | 63.31 | 1,702 | 107,761 | 331,081 | 332.8 K to 331.1 K (-0.51 %) |
Dec 20 2019 | EIDX | Eidos Therapeutics ... | Sinha Uma | Chief Scientific Of ... | Sell | S | 62.49 | 825 | 51,553 | 332,783 | 333.6 K to 332.8 K (-0.25 %) |
Dec 20 2019 | EIDX | Eidos Therapeutics ... | Sinha Uma | Chief Scientific Of ... | Sell | S | 61.61 | 9,973 | 614,480 | 333,608 | 343.6 K to 333.6 K (-2.90 %) |
Dec 11 2019 | EIDX | Eidos Therapeutics ... | Siu Christine | CFO and Secretary | Option Exercise | M | 0.59 | 10,000 | 5,900 | 152,191 | |
Dec 11 2019 | EIDX | Eidos Therapeutics ... | Siu Christine | CFO and Secretary | Option Exercise | M | 0.59 | 10,000 | 5,900 | 152,191 | |
Dec 11 2019 | EIDX | Eidos Therapeutics ... | Siu Christine | CFO and Secretary | Sell | S | 60.05 | 901 | 54,101 | 36,470 | 37.4 K to 36.5 K (-2.41 %) |
Dec 11 2019 | EIDX | Eidos Therapeutics ... | Siu Christine | CFO and Secretary | Sell | S | 60.05 | 901 | 54,101 | 36,470 | 37.4 K to 36.5 K (-2.41 %) |
Dec 11 2019 | EIDX | Eidos Therapeutics ... | Siu Christine | CFO and Secretary | Sell | S | 59.62 | 9,099 | 542,469 | 37,371 | 46.5 K to 37.4 K (-19.58 %) |
Dec 11 2019 | EIDX | Eidos Therapeutics ... | Siu Christine | CFO and Secretary | Sell | S | 59.62 | 9,099 | 542,469 | 37,371 | 46.5 K to 37.4 K (-19.58 %) |
Dec 11 2019 | EIDX | Eidos Therapeutics ... | Siu Christine | CFO and Secretary | Buy | M | 0.59 | 10,000 | 5,900 | 46,470 | 36.5 K to 46.5 K (+27.42 %) |
Dec 11 2019 | EIDX | Eidos Therapeutics ... | Siu Christine | CFO and Secretary | Buy | M | 0.59 | 10,000 | 5,900 | 46,470 | 36.5 K to 46.5 K (+27.42 %) |
Dec 10 2019 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Option Exercise | M | 13.20 | 10,000 | 132,000 | 95,000 | |
Dec 10 2019 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Sell | S | 59.43 | 8,900 | 528,922 | 85,155 | 94.1 K to 85.2 K (-9.46 %) |
Dec 10 2019 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Sell | S | 58.28 | 700 | 40,794 | 94,055 | 94.8 K to 94.1 K (-0.74 %) |
Dec 10 2019 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Sell | S | 56.84 | 400 | 22,736 | 94,755 | 95.2 K to 94.8 K (-0.42 %) |
Dec 10 2019 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Buy | M | 13.20 | 10,000 | 132,000 | 95,155 | 85.2 K to 95.2 K (+11.74 %) |
Dec 05 2019 | EIDX | Eidos Therapeutics ... | Fox Jonathan C | See Remarks | Sell | S | 58.90 | 10,000 | 589,048 | 440,527 | 450.5 K to 440.5 K (-2.22 %) |
Dec 05 2019 | EIDX | Eidos Therapeutics ... | Fox Jonathan C | See Remarks | Gift | G | 0.00 | 1,000 | 0 | 450,527 | 451.5 K to 450.5 K (-0.22 %) |
Dec 05 2019 | EIDX | Eidos Therapeutics ... | Siu Christine | CFO and Secretary | Option Exercise | M | 0.59 | 10,000 | 5,900 | 162,191 | |
Dec 05 2019 | EIDX | Eidos Therapeutics ... | Siu Christine | CFO and Secretary | Option Exercise | M | 0.59 | 10,000 | 5,900 | 172,191 | |
Dec 05 2019 | EIDX | Eidos Therapeutics ... | Siu Christine | CFO and Secretary | Sell | S | 59.39 | 1,200 | 71,272 | 36,470 | 37.7 K to 36.5 K (-3.19 %) |
Dec 05 2019 | EIDX | Eidos Therapeutics ... | Siu Christine | CFO and Secretary | Sell | S | 58.60 | 8,800 | 515,671 | 37,670 | 46.5 K to 37.7 K (-18.94 %) |